{"id":249777,"date":"2023-10-09T00:00:00","date_gmt":"2023-10-09T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/concim0001-2023-biopharma-rheumatoid-arthritis-geographic-focus-china\/"},"modified":"2026-03-31T10:32:00","modified_gmt":"2026-03-31T10:32:00","slug":"concim0001-2023-biopharma-rheumatoid-arthritis-geographic-focus-china-rheumatoid-arthritis-china-in-depth-china","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/concim0001-2023-biopharma-rheumatoid-arthritis-geographic-focus-china-rheumatoid-arthritis-china-in-depth-china\/","title":{"rendered":"Rheumatoid Arthritis &#8211; Geographic Focus: China &#8211; Rheumatoid Arthritis &#8211; China In-Depth (China)"},"content":{"rendered":"<p>Rheumatoid arthritis (<abbr title=\"rheumatoid arthritis\">RA<\/abbr>) is a chronic and progressive autoimmune disease that primarily affects the joints. China has the highest number of <abbr title=\"rheumatoid arthritis\">RA<\/abbr> patients in the world, and disease management is broadly based on three types of treatments: <abbr title=\"conventional disease-modifying antirheumatic drug\">cDMARD<\/abbr>s (e.g., methotrexate, leflunomide); biological <abbr title=\"disease-modifying antirheumatic drug\">DMARD<\/abbr>s (<abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1 inhibitors, anti-CD20 <abbr title=\"monoclonal antibody\">MAb<\/abbr>s, <abbr title=\"interleukin\">IL<\/abbr>-6 inhibitors, and selective costimulation inhibitors); and <abbr title=\"Janus-activated kinase\">JAK<\/abbr> inhibitors. <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1 inhibitors are the most widely prescribed targeted therapies for <abbr title=\"rheumatoid arthritis\">RA<\/abbr> patients refractory to conventional <abbr title=\"disease-modifying antirheumatic drug\">DMARD<\/abbr>s, while other biologics and <abbr title=\"Janus-activated kinase\">JAK<\/abbr> inhibitors largely compete for share of <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1-inhibitor-refractory patients. The approval of cost-effective biosimilars and the incorporation of several therapies into China\u2019s National Reimbursement Drug List have improved patient access to these premium-priced therapies. In this report, we explore how unmet need, pricing, coverage, and regulatory reforms in the A&#038;R landscape of China will likely impact the success of current and future players in this highly lucrative market.<\/p>\n<p><strong>QUESTION ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How large is China\u2019s drug-treatable <abbr title=\"rheumatoid arthritis\">RA<\/abbr> population, and how will drug-treatment rates change during the forecast period?<\/li>\n<li>Which are the most commercially relevant drugs in China\u2019s <abbr title=\"rheumatoid arthritis\">RA<\/abbr> market and why?<\/li>\n<li>What are interviewed experts\u2019 insights into current treatment options? What are the key unmet needs in the management of <abbr title=\"rheumatoid arthritis\">RA<\/abbr> in China?<\/li>\n<li>What are the key market access considerations, and how will they impact the uptake of emerging therapies for <abbr title=\"rheumatoid arthritis\">RA<\/abbr> in China?<\/li>\n<li>What are the key drivers and constraints in this market, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.<\/p>\n<p><strong>Geography<\/strong><\/p>\n<p>China<\/p>\n<p><strong>Primary research <\/strong><\/p>\n<p>Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys of 50 rheumatologists<\/p>\n<p><strong>Epidemiology<\/strong><\/p>\n<p>Diagnosed and drug-treated prevalence of rheumatoid arthritis (<abbr title=\"rheumatoid arthritis\">RA<\/abbr>) in China, with urban and rural breakup; 12-month total and diagnosed prevalence of <abbr title=\"rheumatoid arthritis\">RA<\/abbr> by severity<\/p>\n<p><strong>FORECAST<\/strong><\/p>\n<p>10-year, annualized, drug-level sales and patient share of key <abbr title=\"rheumatoid arthritis\">RA<\/abbr> therapies through 2032, based on primary and secondary market research to formulate bottom-up assumptions<\/p>\n<p><strong>EMERGING THERAPIES<\/strong><\/p>\n<p>Phase 3\/PR: 10+ drugs; Phase 2: 5+ drugs; coverage of select preclinical and Phase 1 products<\/p>\n","protected":false},"template":"","class_list":["post-249777","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-rheumatoid-arthritis","biopharma-therapy-areas-rheumatology","biopharma-product-china-in-depth","biopharma-geography-china","biopharma-geography-us","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249777","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249777\/revisions"}],"predecessor-version":[{"id":576062,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249777\/revisions\/576062"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=249777"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}